Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Read more

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Read more

Events

Calliditas shortlisted for the Capital Market Transaction of the Year at the European Mediscience Awards.

Read more

Press releases

• Aug 15, 2019Interim Report Q2, 2019
• Aug 12, 2019Strategic in-licensing related to autoimmune hepatitis in the US market
• Aug 12, 2019Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q2 report

All press releases

Interim Report Q2 2019

On August 15, 2019, Calliditas Therapeutics published its business update for the second quarter 2019.

• Report
• Presentation
• Press release
• Audio cast

Read the report

Calendar

• Nov 14, 2019Interim report for the period 1 January – 30 September 2019
• Feb 14, 2020Year-end report for the period 1 January – 31 December 2019

All events